Clinical Policy: Quizartinib (Vanflyta)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.646 alerts
Get alerted when Policy CP.PHAR.646 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization coverage of quizartinib for adult members with AML or specified myeloid/lymphoid neoplasms, including initial and continued therapy. It applies to commercial, HIM/ICHRA, and Medicaid lines of business, subject to applicable state Medicaid provisions.
The policy added single-agent quizartinib therapy for relapsed or refractory AML to the covered initial-therapy options.
The policy added maintenance-therapy options after allogeneic hematopoietic cell transplantation and after prior FLT3-inhibitor therapy when no transplant is planned.
The policy added off-label criteria for myeloid, lymphoid, or mixed-phenotype neoplasms with eosinophilia and FLT3 rearrangement.
The AML initial approval duration was revised to 12 months.
Continued-therapy criteria were revised to require current treatment for a covered indication rather than specifically referring only to AML.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.